The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2024Assessment of Longitudinal Imaging Using Radiolabeled AV-133 in Early and Prodromal Parkinson’s Disease
Study Rationale: The clinical phase of Parkinson’s disease (PD) is preceded by a prodromal phase of progressing neurodegeneration that can last many years. Imaging markers such as radiolabeled AV-133...
-
Clinical Intervention Awards, 2009MASTER PD: Magnetic Stimulation for the Treatment of Motor and Mood Symptoms of Parkinson's Disease: A Four-Center, Sham-Controlled, Parallel Group Study
Objective/Rationale:
To determine the efficacy and duration of benefit of noninvasive brain stimulation with repetitive transcranial magnetic stimulation (rTMS) to modulate brain activity in order to... -
MJFF Research Grant, 2009The Validation of Anxiety Scales in Parkinson's Disease
Objective/Rationale:
This study has two objectives:
1. To assess the occurrence and symptoms of anxiety disorders in Parkinson's disease, including atypical anxiety syndromes, and anxiety states... -
LRRK2 Cohort Consortium, 2012Parkinson’s Institute LRRK2 Cohort: Clinical Phenotype, Pre/Non-Motor and Environmental Risk Assessment
Objective/Rationale:
The objective of this award is to better understand the clinical symptoms of patients that carry the most common genetic risk factor for PD the LRRK2 G2019S variant and what role... -
Research Grant, 2017Improving Participation in Clinical Trials in Individuals with Atypical Parkinsonian Syndromes through Virtual Research Visits (ImPaCT-Atypical)
Objective/Rationale:
The Michael J. Fox Foundation's Fox Trial Finder is designed to facilitate and increase the participation of individuals with Parkinson's disease (PD) and degenerative... -
Research Grant, 2016Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease
Study Rationale:
Nilotinib, a drug approved for chronic myelogenous leukemia, inhibits the protein c-Abl. Higher brain levels of c-Abl are associated with Parkinson's disease (PD), and laboratory...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.